Carcinoma, Bronchogenic Clinical Trials

Active, not recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

NCT02411448

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: UCLA Hematology/Oncology - Santa Monica Los Angeles, California, United States

St. Charles Health System Denver, Colorado, United States

The Gastroenterology Group, P.C. Honolulu, Hawaii, United States

Cancer Center of Kansas Wichita, Kansas, United States

View all 106 locations

View Trial Details

Active, not recruiting

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

NCT05845671

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations: City of Hope Cancer Center Duarte, California, United States

Outpatient CTRC Aurora, Colorado, United States

University of Colorado Hospital Aurora, Colorado, United States

University of Michigan Rogel Cancer Center Ann Arbor, Michigan, United States

View Trial Details

Active, not recruiting

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667

Conditions: Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +79 more
Locations: Alaska Clinical Research Center Anchorage, Alaska, United States

Genesis Cancer Center Hot Springs, Arkansas, United States

Chan Soon-Shiong Institute for Medicine El Segundo, California, United States

MemorialCare Health System Fountain Valley, California, United States

View all 35 locations

View Trial Details

Active, not recruiting

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

NCT05651022

Conditions: Adenocarcinoma, Bronchial Neoplasms, CRC (Colorectal Cancer), +31 more
Locations: University of Southern California- Norris Cancer Center Los Angeles, California, United States

Hoag Memorial Hospital Presbyterian Newport Beach, California, United States

Winship Cancer Institute of Emory University Atlanta, Georgia, United States

The Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

View Trial Details

Active, not recruiting

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

NCT02715284

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations: GSK Investigational Site Birmingham, Alabama, United States

GSK Investigational Site Goodyear, Arizona, United States

GSK Investigational Site Scottsdale, Arizona, United States

GSK Investigational Site Fayetteville, Arkansas, United States

View all 105 locations

View Trial Details

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Limited-Stage Small Cell Lung Cancer, +8 more
Locations: OPN-Glendale Arcadia, California, United States

OPN-Los Alamitos Los Alamitos, California, United States

Southern California Permanente Group Los Angeles, California, United States

Emad Ibrahim, MD, Inc Redlands, California, United States

View all 129 locations

View Trial Details

Active, not recruiting

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations: Rocky Mountain Cancer Center, LLP Boulder, Colorado, United States

Georgetown University Medical Center Washington D.C., District of Columbia, United States

MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute, Washington D.C., District of Columbia, United States

Illinois Cancer Specialists Arlington Heights, Illinois, United States

View all 35 locations

View Trial Details

Active, not recruiting

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

NCT02988960

Conditions: Advanced Solid Tumors Cancer, Bronchial Neoplasms, Carcinoma, +23 more
Locations: The Angeles Clinic and Researc /ID# 156324 Los Angeles, California, United States

The University of Chicago Medical Center /ID# 155264 Chicago, Illinois, United States

Massachusetts General Hospital /ID# 155267 Boston, Massachusetts, United States

Carolina BioOncology Institute /ID# 155265 Huntersville, North Carolina, United States

View all 22 locations

View Trial Details

Active, not recruiting

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Beverly Hills Cancer Center Beverly Hills, California, United States

The Oncology Institute of Hope and Innovation Glendale, California, United States

Moores Cancer Center at UC San Diego La Jolla, California, United States

Keck Medicine of University of Southern California Los Angeles, California, United States

View all 77 locations

View Trial Details

Active, not recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

NCT05544929

Conditions: Adenocarcinoma, Adenocarcinoma, Clear Cell, Adenoma, +83 more
Locations: Massachusetts General Hospital . Boston, Massachusetts, United States

Massachusetts General Hospital Boston, Massachusetts, United States

NYU School of Medicine New York, United States

University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States

View all 19 locations

View Trial Details

Carcinoma, Bronchogenic

Carcinoma, Bronchogenic trial results

Related conditions